No profile data available.
Amphastar Pharmaceuticals, Inc. (AMPH) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Rancho Cucamonga, United States, with about 1,976 full-time employees.
It reported revenue of $731.97 million for fiscal year 2024, up 13.6% from fiscal year 2023, and net income of $159.52 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $191.84 million, up 0.3% from a year before. United States was its largest region in fiscal year 2025, with 95% of revenue. Its market capitalization was $1.13 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Amphastar Pharmaceuticals reported $731.97 million in revenue for fiscal year 2024, up 13.6% from $644.40 million in fiscal year 2023. In Q3 2025 revenue was $191.84 million.
United States: 95% of revenue by region in fiscal year 2025, followed by France (5%).
$1.13 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Nektar Therapeutics (NKTR), Sana Biotechnology, Inc. (SANA), Oculis Holding AG (OCS), MannKind Corporation (MNKD).